title: Current Status of Hepatic Arterial Infusion Chemotherapy.
abstract: BACKGROUND
  Hepatic arterial infusion chemotherapy (HAIC) is frequently used to treat advanced hepatocellular carcinoma (HCC) in Asian countries. However, there is a lack of evidence supporting the use of HAIC.
  
  
  CONCLUSIONS
  Many studies report high response rates in patients with advanced HCC receiving HAIC, and clinical responses translate to survival benefits. Therefore, prediction of an antitumor response is important in selecting appropriate treatments. There are no proven post-sorafenib therapeutic measures or procedures for HCC patients with poor liver function, and HAIC is one of the few options for patients in these situations. Despite studies showing its effectiveness, the use of HAIC for treatment of advanced HCC is unclear because convincing data from large-scale randomized clinical trials are lacking. For HAIC to become a standard treatment for HCC, such trials must establish its efficacy compared with other HCC therapies; prediction of antitumor response in HAIC may aid trial design, and a multi-center, open-labelled, randomized clinical trial of HAIC in advanced HCC is currently in progress. Optimization of HCC treatment protocols and regimens is also required.
  
  
  CONCLUSIONS
  We think that both HAIC and sorafenib are effective treatments for advanced HCC, and this review presents evidence supporting this contention.
authors.affiliation: Department of Gastroenterology and Hepatology, Kyoundo Hospital of the Sasaki Institute, Tokyo, Japan.
authors.forename: Shuntaro
authors.initials: S
authors.lastname: Obi
authors.affiliation: Department of Gastroenterology and Hepatology, Kyoundo Hospital of the Sasaki Institute, Tokyo, Japan.
authors.forename: Shinpei
authors.initials: S
authors.lastname: Sato
authors.affiliation: Department of Gastroenterology and Hepatology, Kyoundo Hospital of the Sasaki Institute, Tokyo, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Kawai
keywords: Arterial infusion; Chemotherapy; Clinical trial; Hepatocellular carcinoma; Sorafenib